Currently out of the existing stock ratings of Rachel Vatnsdal, 4 are a SELL (17.39%), 8 are a HOLD (34.78%), 11 are a BUY (47.83%).

Rachel Vatnsdal

Work Performance Price Targets & Ratings Chart

Analyst Rachel Vatnsdal, currently employed at JPMORGAN, carries an average stock price target met ratio of 65.24% that have a potential upside of 20.98% achieved within 91 days.

Rachel Vatnsdal’s has documented 54 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on HSIC, Henry Schein at 12-Aug-2024.

Wall Street Analyst Rachel Vatnsdal

Analyst best performing recommendations are on MYGN (MYRIAD GENETICS).
The best stock recommendation documented was for MYGN (MYRIAD GENETICS) at 8/7/2023. The price target of $17 was fulfilled within 2 days with a profit of $0.47 (2.69%) receiving and performance score of 13.45.

Average potential price target upside

of $56.52 (27.42%) on DHR (DANAHER).
of $40.06 (3.54%) on MTD (METTLER-TOLEDO INTERNATIONAL).
of $33.03 (22.35%) on RGEN (REPLIGEN).

AMRS Amyris QDEL Quidel MTD Mettler-Toledo International HSIC Henry Schein DHR Danaher MYGN Myriad Genetics PACB Pacific Biosciences of California PDCO Patterson Companies RGEN Repligen

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Laurence Alexander (JEFFERIES)